$ASND

$245.85 +$0.70 (0.29%) Close

$ASND Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 62.0M shares outstanding

Who owns ASND?

By type of holder

Institutions 100.0% Insiders 0.0% Everyone else 0.0%

Concentration Top 10 holders own 69.1%

Ra Capital Management, L.P. 16.6% · T. Rowe Price Investment Management, Inc. 10.9%

Institutional ownership

100.0%

0 pts vs last qtr

Institutional holders

311

+39 vs last qtr

Net shares bought

+4.2M

by institutions in Q2 2026

New / sold out

91 / 52

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Jupiter Topco LLC NEW +3.6M
BlackRock, Inc. +1.6M

Biggest sellers in Q2 2026

Artisan Partners Limited Partnership −596.2K
Nomura Asset Management International Inc. SOLD OUT −556.4K

Who is planning to sell?

Notices of proposed sale, last 12 months

$106M

27 notices from 15 people

Shares covered

466.4K

0.75% of the company

Arranged in advance

37%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Jan Moller Mikkelsen Ceo $43.8M
Mikkelsen Jan Moller Officer 10b5-1 $18.4M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

There are not yet two fiscal years of reported share counts for Ascendis Pharma A/S.

How patient are the owners?

Institutional shares by how long they've been held

5+ years64% 3–5 years14% 1–3 years11% Under 1 year12%

Quarterly turnover

13.0%

of institutional shares changed hands

Top 10 managers, median time held

5 years

Super Investors

Investment managers reporting ASND on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
RC Ra Capital Management, L.P.	10.3M	16.59%	Unchanged	≤2021	23.8%
Shares held by quarter Peak holding10.3M (Q1'25) Change over 8 quarters+571.1K Share of the company16.590% Ra Capital Management, L.P.'s full portfolio →
TR T. Rowe Price Investment Management, Inc.	6.8M	10.90%	+592.8K (+9.6%)	2022	1.2%
Shares held by quarter Peak holding6.8M (Q2'26) Change over 8 quarters+5.0M Share of the company10.900% T. Rowe Price Investment Management, Inc.'s full portfolio →

Ra Capital Management, L.P.

10.3M

% of company

16.59%

Change vs last qtr

Unchanged

Held since

≤2021

T. Rowe Price Investment Management, Inc.

6.8M

% of company

10.90%

Change vs last qtr

+592.8K (+9.6%)

Held since

2022

28 more super investors behind a free account

See every manager holding Ascendis Pharma A/S, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting ASND on Form N-PORT; together they hold 36.5% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
TR T. Rowe Price Capital Appreciation Fund T. Rowe Price Capital Appreciation Fund, Inc.	$627M	2.7M	4.42%	0.95%	March 31, 2026
MM MFS Mid Cap Growth Fund MFS Series Trust IV	$299M	1.3M	2.06%	2.17%	February 28, 2026

T. Rowe Price Capital Appreciation Fund

T. Rowe Price Capital Appreciation Fund, Inc.

Position value

$627M

% of company

4.42%

% of the fund

0.95%

As of

March 31, 2026

MFS Mid Cap Growth Fund

MFS Series Trust IV

Position value

$299M

% of company

2.06%

% of the fund

2.17%

As of

February 28, 2026

23 more funds behind a free account

See every fund holding Ascendis Pharma A/S and how much of the fund the position is.

Comments